Prevalence of gastrointestinal disorders having an impact on tablet levothyroxine absorption: should this formulation still be considered as the first-line therapy?

Castellana, Marco; Castellana, Carlo; Giovanella, Luca; Trimboli, Pierpaolo

Castellana, Marco; Castellana, Carlo; Giovanella, Luca; Trimboli, Pierpaolo.

Afiliación

Castellana M; National Institute of Gastroenterology "S. De Bellis", Castellana Grotte, Bari, Italy.
Castellana C; Margherita di Savoia 93, Putignano, 70017, Bari, Italy.
Giovanella L; Clinic for Nuclear Medicine and Competence Center for Thyroid Diseases, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
Trimboli P; Clinic for Nuclear Medicine and Competence Center for Thyroid Diseases, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland. pierpaolo.trimboli@gmail.com.

Endocrine ; 67(2): 281-290, 2020 02.

Article en En | MEDLINE | ID: mdl-31953721

Asunto(s)

Infecciones por Helicobacter; Helicobacter pylori; Infecciones por Helicobacter/tratamiento farmacológico; Infecciones por Helicobacter/epidemiología; Humanos; Prevalencia; Revisiones Sistemáticas como Asunto; Comprimidos; Tiroxina

Palabras clave

Hypothyroidism; Levothyroxine; Liquid; Malabsorption; Review; Soft gel

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Helicobacter pylori / Infecciones por Helicobacter Tipo de estudio: Prevalence_studies / Risk_factors_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Endocrine Asunto de la revista: ENDOCRINOLOGIA Año: 2020 Tipo del documento: Article País de afiliación: Italia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google